The current status of the use of palonosetron

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 10, 2013, Pages 1281-1284

  Navari, Rudolph ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiemetics; Chemotherapy; Nausea and emesis; Palonosetron

Indexed keywords

AZASETRON; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PALONOSETRON; RAMOSETRON; TROPISETRON;

ANTIEMETIC ACTIVITY; BINDING AFFINITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG HALF LIFE; HUMAN; MOLECULAR INTERACTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; ISOQUINOLINES; NAUSEA; QUINUCLIDINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 84878869033     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.799141     Document Type: Review

References (21)

1. Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 2010;6:1074-84
2. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69:1853-8
3. Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol 2012;9:20-6
4. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009;28:1-7
5. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:186-95
6. Geling O, Eichler H. Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-94
7. Egler RM, Lee CH, Smith W, et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 1995;114:860-6
8. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626:193-9
9. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
10. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist; a phase III, single dose trial versus dolasetron. Cancer 2003;98:2473-82
11. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single dose of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
12. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol 2009;10:115-24
13. Aapro M, Fabi A, Nole F, et al. Doubleblind, randomized, controlled-study of the efficacy and tolerability of palonosetron plus dexamethasone for one day with or without dexamethasone on days two and three in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21:1083-8
14. Celio L, Denaro A, Agustoni F, et al. Palonosetron plus one-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 2012;10:65-71
15. Boccia R, Grunberg S, Franco-Gonzales E, et al. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 2013; In press
16. Botrel T, Clark O, Clark L, et al. Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer 2011;19:823-32
17. Fabi A, Malaguti P. An update on palonosetron hydrochloride for the treatment of radio/chemotherapyinduced nausea and vomiting. Expert Opin Pharmacother. 2013;14(5):629-40
18. Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 2012;20(7):1507-14
19. Yavas C, Dogan U, Yavas G, et al. Acute effect of palonosetron on electrocardiographic parameters in cancer patients; a prospective study. Support Care Cancer 2012;20:2343-7
20. NCCN Clinical Practice Guidelines in Oncology version 1 2012; Antiemesis. National Comprehensive Cancer Network (NCCN). Available from: http://www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf [Last accessed 31 January 2012]
21. Einhorn LH, Brames ML, Dreicer R, et al. Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007;15:1293-300